<DOC>
	<DOC>NCT02456675</DOC>
	<brief_summary>A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.</brief_summary>
	<brief_title>INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Men and women, aged 18 years or older Histologically confirmed diagnosis of classical HL Must be relapsed or refractory after autologous stem cell transplant (ASCT) and/or 2 or more prior chemotherapy regimens Must have had prior treatment with brentuximab vedotin or not a candidate for treatment with brentuximab vedotin Eastern Cooperative Oncology Group (ECOG) 0 to 2 Laboratory parameters not within the protocoldefined range Received an investigational study drug within 28 days or 5 halflives (whichever is longer) prior to receiving the first dose of study drug. Received any approved anticancer medications within 21 days or 5 halflives (whichever is longer) prior to receiving their first dose of study drug EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent). Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy Received autologous stem cell transplant within 28 days or allogeneic transplant within 3 months prior to first dose of study drug History of lymphoma involving the central nervous system Evidence of active or prior hepatitis infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Refractory Hodgkin lymphoma</keyword>
	<keyword>Relapsed Hodgkin Lymphoma</keyword>
</DOC>